The Tc1/Tc2 profiles and anti-tumor immune response in advanced ovarian cancer patients undergo-ing paclitaxei and carboplatin chemotherapy
10.3760/cma.j.issn.0254-5101.2009.09.019
- VernacularTitle:卵巢癌患者一线化疗后Tc1/Tc2亚群漂移及免疫应答功能动态变化的研究
- Author:
Qinmei FENG
;
Wen DI
;
Xia WU
- Publication Type:Journal Article
- Keywords:
Ovarian cancer;
Chemotherapy;
Tc1/Tc2;
Immune response
- From:
Chinese Journal of Microbiology and Immunology
2009;29(9):847-850
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the changes of Tc1/Tc2 profiles and the cytotoxic function of CD8~+ cells in ovarian cancer patients undergoing paclitaxel and carboplatin chemotherapy, so as to identify whether there is a "window period" of anti-tumor immune suppression reverse after chemotherapy. Methods Blood samples from each ovarian cancer patient were obtained before (S_0) and at day 5-7 (S_1), day 12-14 (S_2) and day 25-28 (S_3) after chemotherapy in 13 patients. Thirteen age-matched healthy female volunteers were enrolled as a control group. Flow cytometry technique was employed to analyze the proportion of Tc1/Tc2. The numbers of specific IFN-γ, secreting CD8~+ cells were also calculated after peripheral lymphocytes had been stimulated with self tumor lysates. Results The proportion of Tel in CD8~+ cells increased re-markably on S2 while the proportion of Tc2 in CD8~+ cells remained no significant changes after chemothera-py. The ratio of Tc1 to Tc2 cells reached the highest on S_2. IFN-γ/secreting CD8~+ T cells also increased re-markably on S_2, especially when CD8~+ T cells were stimulated with autologous tumor antigen. Conclusion Paclitaxel and carboplatin induce the changes of Tc1/Tc2 profile and augment anti-tumor immune response by immune reconstitution. It probably turns out that the "window period" during immune reconstitution offers a best opportunity for cancer immunotherapy.
